⌕
Alexion Pharmaceuticals · ALXN · Nasdaq
$182.50at last closeTenet 64 · Solid
Compare
$182.50at last closeTenet 64 · Solid

Alexion Pharmaceuticals (ALXN) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~18.4%/yr (FY16→FY20), net margin 9.9%, and free cash flow (~$2.9B) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY16–FY20
Revenue ($M)▲21.6%
6,069.9
FY16→FY20CAGR +18.4%/yr
Net income ($M)▼74.9%
603.4
one-off year: see footnoteCAGR +10.9%/yr
Free cash flow ($M)▲50.0%
2,896.2
FY16→FY20CAGR +40.0%/yr
Diluted EPS▼74.6%
2.72
buyback-liftedCAGR +11.5%/yr
What the receipts whisper · what a headline number hides
Share count
−2.2%

227.0mn → 222.0mn diluted shares since FY16. Part of EPS growth is the shrinking denominator. Watch net income too.

Capex
$106.7M

−31.0% YoY in FY20 · 1.8% of revenue.

Returns vs FCF
18%

$0.5B returned vs $2.9B of FCF in FY20. Buybacks covered by cash flow.

What the income statement says · FY16–FY20
Where every revenue dollar goes · FY20 ($M)6069.9Revenue−553.5COGS5516.4Gross profit−1002.9R&D−1399.9SG&A632.3Op income−28.9Tax & other603.4Net income

10¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%FY16FY20

Over this window: gross 91.6% → 90.9%. Net margin 9.9% is more than double the sector median.

The receipt · income statement · FY16–FY20 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY20FY19FY18FY17FY16YoYCAGR 16→20
Revenue & profitability
Revenue
6,261.66,069.94,991.14,131.23,551.13,084.1▲21.6%+18.4%
Cost of revenue
567.2553.5394.5374.3454.2258.3▲40.3%+21.0%
Gross profit
5,694.45,516.44,596.63,756.93,096.92,825.8▲20.0%+18.2%
Research & development
1,284.41,002.9881.91,913.4878.4757.2▲13.7%+7.3%
Selling, general & admin
1,422.91,399.91,261.11,111.81,094.4953.0▲11.0%+10.1%
Total operating expenses
5,121.44,884.12,476.23,487.32,469.52,158.4▲97.2%+22.6%
Operating incomefeeds ROC rank
573.0632.32,120.4269.6627.4667.4▼70.2%−1.3%
Other income, net
−65.0−63.358.4−27.4−79.6−91.2——
Pretax income
508.0569.02,178.8242.2547.8576.2▼73.9%−0.3%
Income tax
−27.0−34.4−225.5164.6104.5176.8▲84.7%—
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
535.0603.42,404.377.6443.3399.4▼74.9%+10.9%
Per share
Diluted EPSbuyback-sensitive
3.082.7210.700.351.971.76▼74.6%+11.5%
Diluted shares (mn)
222.60222.00224.80224.50225.40227.00▼1.2%−0.6%
Margins
Gross margin73rd pct in Healthcare
90.9%90.9%92.1%90.9%87.2%91.6%▼1.2pp−0.7pp
Operating margin
9.2%10.4%42.5%6.5%17.7%21.6%▼32.1pp−11.2pp
Net margin74th pct in Healthcare
8.5%9.9%48.2%1.9%12.5%13.0%▼38.2pp−3.0pp
† TTM = trailing four quarters through 2021-03-31.FY16 effective tax rate was 31% vs a 19% norm for this window, likely a one-time item; see the filing.FY18 effective tax rate was 68% vs a 19% norm for this window, likely a one-time item; see the filing.
FY08 – FY15 · 8 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 8 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2021-02-08 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Alexion Pharmaceuticals' revenue last fiscal year?

Alexion Pharmaceuticals reported revenue of $6,069.9M in fiscal 2020, up 21.6% from fiscal 2019.

What was Alexion Pharmaceuticals' net income?

Alexion Pharmaceuticals reported net income of $603.4M in fiscal 2020, a net margin of 9.9%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.